TcMedicine

Archive for September 26th, 2008

ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, presented data from the company’s novel compound, ANAVEX 1-41, targeting

Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD). The study evaluated the

GE Healthcare, a unit of the General Electric Company (NYSE:GE), announced positive results from a Phase I clinical trial of GE-067, a [18F]-labeled PET diagnostic imaging agent being developed by the company to assist in the detection of brain beta-amyloid. The results, presented

New results announced at the International Congress on Alzheimer’s disease (ICAD) in Chicago indicate that a medical nutrition product (SouvenaidTM) may offer a new option in the management of people with mild Alzheimer’s disease.

The randomised, double-blind,

Alzheimer Scotland welcomes the results of this Phase 2 study on a new treatment for dementia.

Jim Jackson, Chief Executive at Alzheimer Scotland, said, “The initial results of this trial are exciting: responses are extremely encouraging compared to existing treatments.

Researchers using conventional, as opposed to high powered MRI equipment, and computer-based methods to analyze the scans, are breaking new ground in the diagnosis of the telltale signs of Alzheimer’s Disease, increasing the likelihood that there will be reliable ways of

Alzheimer’s Society comment on new research presented at the International Conference on Alzheimer’s Disease (ICAD).

High blood pressure doubles the risk of Alzheimer’s disease and increases the risk of stroke. This study highlights that it is becoming

Alzheimer’s Society comment: Adults with Alzheimer’s disease who are talked to like children are more resistant to care.

This is according to new research presented at the International Conference on Alzheimer’s Disease (ICAD).

Good communication

Researchers at Boston University School of Medicine (BUSM) have, for the first time, found that angiotensin receptor blockers (ARBs) - a particular class of anti-hypertensive medicines - are associated with a striking decrease in the occurrence and progression of dementia. Data from

A Dominican family from Manhattan that has been ravaged by Alzheimer’s disease is the focus of one of a powerful series of BBC World News America films looking at the condition that could already affect as many as twenty million people worldwide.